Spinelab Raises Series C from BioMedInvest and VI Partners Leads (press release)
Spinelab AG, a privately held company, specialized in developing motion preserving stabilization systems for the spine, announced today that it has raised Swiss francs 4.7 million in a Series C financing round. Lead investors are BioMedInvest and VI Partners. Spinelab has raised Swiss francs 20 million since its first venture round end of 2006.
“Spinelab has rigorously documented the clinical performance of its flagship product, the motion preservation system Elaspine™, over the last three years. This new funds will allow Spinelab to initiate commercial activities in Europe and to complete the development of its second core product”, said Thomas Zehnder, President & CEO of Spinelab.
Gerard Moufflet, Chairman of Spinelab added: “With a strong database of over 100 documented clinical cases with Elaspine™ in Europe, Spinelab is poised to demonstrate the superior clinical benefits and to position Elaspine™ as a leading device in this field.”
About Spinelab
Spinelab’s core product Elaspine™ is a pedicle screw based posterior motion preservation system for thoracolumbar spine. The key element is an elast...
